A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma


Por: Manier, S, Puig, N, Leleu, X, Oriol, A, Hulin, C, Garcia-Sanz, R, Corre, J, San-Miguel, J, Facon, T, Lee, H, Forsberg, P, Chatterjee, K, Svensson, A, Talati, C, He, SY, Doerr, T, Arriola, E, Dillon, M, Lin, JNF, Nguyen, L, Wang, F and Mateos, MV

Publicada: 1 dic 2025 Ahead of Print: 1 dic 2025
Resumen:


Filiaciones:
Manier, S:
 Lille Univ, Ctr Hosp Univ Lille, Dept Hematol, Lille, France

Puig, N:
 Hosp Univ Salamanca, Ctr Invest Biomed Red Canc, Consejo Super Invest Cienticas, IBSAL,Inst Biol Mol & Celular Canc,Hematol Dept, Salamanca, Spain

Leleu, X:
 CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

 CIC Inserm 1402, Poitiers, France

:
 Hosp Germans Trias i Pujol, Inst Catala Oncol, Inst Josep Carreras, Barcelona, Spain

Hulin, C:
 Hop Haut Leveque, Ctr Hosp Univ CHU Bordeaux, Serv Hematol, Pessac, France

Garcia-Sanz, R:
 Hosp Gen Univ Gregorio Maranon, Hematol Dept, CIBERONC IBSAL, Madrid, Spain

Corre, J:
 Univ Canc Ctr Toulouse, Inst Natl Sante & Rech Med, Unite Genom Myelome, Toulouse, France

San-Miguel, J:
 Canc Ctr Clin Univ Navarra, Inst Invest Sanitaria Navarra, Ctr Invest Med Aplicada, CIBER-ONC CB16-12-00369 & CB16-12-00489, Pamplona, Spain

Facon, T:
 Univ Lille, Paris, France

 French Acad Med, Dept Haematol, Paris, France

Lee, H:
 Sarah Cannon Res Inst, Nashville, TN USA

Chatterjee, K:
 AbbVie Inc, N Chicago, IL USA

Svensson, A:
 AbbVie Inc, N Chicago, IL USA

Talati, C:
 AbbVie Inc, N Chicago, IL USA

He, SY:
 AbbVie Inc, N Chicago, IL USA

Doerr, T:
 AbbVie Inc, N Chicago, IL USA

Arriola, E:
 AbbVie Inc, N Chicago, IL USA

Dillon, M:
 AbbVie Inc, N Chicago, IL USA

Lin, JNF:
 AbbVie Inc, N Chicago, IL USA

Nguyen, L:
 AbbVie Inc, N Chicago, IL USA

Wang, F:
 AbbVie Inc, N Chicago, IL USA

Mateos, MV:
 CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

 CIC Inserm 1402, Poitiers, France

 Hosp Univ Salamanca, IBSAL, CIC, Ciberonc, Salamanca, Spain
ISSN: 00064971





Blood
Editorial
American Society of Hematology, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 146 Número:
Páginas: 2288-2289
WOS Id: 001660396400038

MÉTRICAS